Navigation Links
Surefire Medical's Anti-Reflux Infusion System May Eliminate Coiling, Lower Cost Of Embolization Procedures
Date:9/16/2013

WESTMINSTER, Colo., Sept. 16, 2013 /PRNewswire/ -- Surefire Medical, Inc., the developer of a brand new class of infusion systems designed to maximize direct-to-tumor drug delivery without reflux, today announced that presentations at the Cardiovascular and Interventional Radiological Society (CIRSE) meeting make the economic case for use of the new Surefire Infusion System (SIS).   Research presented today in Barcelona found that:

  • The SIS catheter group had a significant reduction in procedure time, fluoroscopy time, and contrast dose in pre-treatment angiograms
  • Without use of coils, no non-target embolization occurred in the SIS group during treatment
  • Using the SIS catheter to protect non-target organs costs significantly less than coil embolization in direct-to-tumor cancer treatment

"The Surefire Infusion System is a viable first-line alternative to traditional retrievable coil embolization for protecting non-target organs and may lead to decreased overall costs, procedure time, fluoroscopy time, and contrast exposure when treating cancer patients with radioembolization," said principal investigator Steven Kikolski, MD of the University of California San Diego (UCSD).

Additional SIS-focused presentations at CIRSE

Five additional presentations and posters at CIRSE focusing on the Surefire Infusion System

  • Confirm the safety of performing chemoembolization and radioembolization procedures without coiling
  • Present a pilot study of a single procedure for mapping and radioembolization
  • Detail the new ability to measure blood pressure changes that can signal the endpoint of embolization
  • Discuss the feasibility of bariatric embolization to reduce obesity

"We are extremely gratified by the rapidly growing body of clinical evidence showing that both patients and medical institutions benefit by the use of the Surefire Infusion System for cancer treatment," said Surefire President and CEO Jim Chomas.  "The new technology advances the better tolerated, minimally-invasive embolization techniques.  It reduces procedure time and cost, and makes treatment feasible for patients previously thought untreatable."

About Surefire Medical

Surefire Medical, Inc., based in Westminster, Colo., was founded in 2009 to develop innovative infusion systems for the interventional radiology and interventional oncology markets.  Surefire's infusion systems are designed to precisely deliver embolic agents through a unique microcatheter with an expandable tip that collapses in forward flow and dynamically expands to the vessel wall in reverse flow in order to maximize targeted delivery, minimize reflux and reduce damage to healthy tissue.  The Surefire Infusion System-ST, LT and specialty catheters have received regulatory approval in the U.S., Europe, and New Zealand.  For more information, please visit www.surefiremedical.com.

CIRSE BOOTH #1


'/>"/>
SOURCE Surefire Medical, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Surefire Medical Launches Next Generation Infusion System ST-LT and Specialty Catheters at SIR - Maximizing Targeted Delivery of Embolics Without Reflux
2. Nile Therapeutics Announces Top-Line Results in Clinical Trial Evaluating the Subcutaneous Infusion of Cenderitide, Meets Primary Endpoint
3. At RSNA, DR Systems Will Exhibit RIS, Reporting, Peer Review Systems
4. Clionsky Neuro Systems (CNS-Neuro) Announces Publication of Study Finding Elderly Patients Unable to Recognize Their Memory Loss
5. Dicom Systems and USARAD.com Announce Partnership and Introduce Beta Version of XMRI.com, New System by USARAD.com
6. Ellmans Pelleve™ Wrinkle Reduction System featured in "Sexy Eyes" segment on The Doctors
7. Bacterin Signs Distribution Agreement with Jeil for LeForte Craniomaxillofacial System
8. BioPower Systems Awarded $5 Million from Victorian Government
9. Echo Therapeutics Announces Positive Results of Clinical Trial of its Symphony® Transdermal Continuous Glucose Monitoring (tCGM) System in Patients With Type 1 and Type 2 Diabetes
10. Varian Medical Systems Schedules First Quarter FY2012 News Release and Conference Call
11. Quanterix Develops Microfluidic Consumable That Will Enable Next Generation Molecular Diagnostic Systems based on Single Molecule Array Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... ... Parallel 6 , the leading software as a service (SaaS) provider ... Patient Encounter CONSULT module which enables both audio and video telemedicine communication between the ... the CONSULT module, patients and physicians can schedule a face to face virtual patient ...
(Date:6/27/2016)... , June 27, 2016  Liquid Biotech ... the funding of a Sponsored Research Agreement with ... tumor cells (CTCs) from cancer patients.  The funding ... CTC levels correlate with clinical outcomes in cancer ... data will then be employed to support the ...
(Date:6/24/2016)... SAN DIEGO , June 24, 2016 /PRNewswire/ ... that more sensitively detects cancers susceptible to PARP ... individual circulating tumor cells (CTCs). The new test ... of HRD-targeted therapeutics in multiple cancer types. ... therapies targeting DNA damage response pathways, including PARP, ...
(Date:6/23/2016)... ... 2016 , ... Mosio, a leader in clinical research patient ... and Retention Tips.” Partnering with experienced clinical research professionals, Mosio revisits the hurdle ... and strategies for clinical researchers. , “The landscape of how patients receive and ...
Breaking Biology Technology:
(Date:6/7/2016)... TORONTO , June 7, 2016  Syngrafii ... begun a business relationship that includes integrating Syngrafii,s ... pilot branch project. This collaboration will result in ... for the credit union, while maintaining existing document ... http://photos.prnewswire.com/prnh/20160606/375871LOGO ...
(Date:6/2/2016)... 2016   The Weather Company , an IBM Business ... industry-first capability in which consumers will be able to interact ... questions via voice or text and receive relevant information about ... Marketers have long sought an advertising solution that can ... personal, relevant and valuable; and can scale across millions of ...
(Date:5/24/2016)... , May 24, 2016 Ampronix facilitates superior patient care by providing unparalleled ... medical LCD display is the latest premium product recently added to the range of ... ... ... Sony 3d Imaging- LCD Medical Display- Ampronix News ...
Breaking Biology News(10 mins):